Bayesian clinical trials in action
- 18 June 2012
- journal article
- review article
- Published by Wiley in Statistics in Medicine
- Vol. 31 (25), 2955-2972
- https://doi.org/10.1002/sim.5404
Abstract
Although the frequentist paradigm has been the predominant approach to clinical trial design since the 1940s, it has several notable limitations. Advancements in computational algorithms and computer hardware have greatly enhanced the alternative Bayesian paradigm. Compared with its frequentist counterpart, the Bayesian framework has several unique advantages, and its incorporation into clinical trial design is occurring more frequently. Using an extensive literature review to assess how Bayesian methods are used in clinical trials, we find them most commonly used for dose finding, efficacy monitoring, toxicity monitoring, diagnosis/decision making, and studying pharmacokinetics/pharmacodynamics. The additional infrastructure required for implementing Bayesian methods in clinical trials may include specialized software programs to run the study design, simulation and analysis, and web‐based applications, all of which are particularly useful for timely data entry and analysis. Trial success requires not only the development of proper tools but also timely and accurate execution of data entry, quality control, adaptive randomization, and Bayesian computation. The relative merit of the Bayesian and frequentist approaches continues to be the subject of debate in statistics. However, more evidence can be found showing the convergence of the two camps, at least at the practical level. Ultimately, better clinical trial methods lead to more efficient designs, lower sample sizes, more accurate conclusions, and better outcomes for patients enrolled in the trials. Bayesian methods offer attractive alternatives for better trials. More Bayesian trials should be designed and conducted to refine the approach and demonstrate their real benefit in action. Copyright © 2012 John Wiley & Sons, Ltd.This publication has 57 references indexed in Scilit:
- Bayesian Robustness Modelling of Location and Scale ParametersScandinavian Journal of Statistics, 2011
- The BUGS project: Evolution, critique and future directionsStatistics in Medicine, 2009
- Bayesian clinical trials at the University of Texas M. D. Anderson Cancer CenterClinical Trials, 2009
- Phase I/II study of gemtuzumab ozogamicin added to fludarabine, melphalan and allogeneic hematopoietic stem cell transplantation for high-risk CD33 positive myeloid leukemias and myelodysplastic syndromeLeukemia, 2007
- A survey of population analysis methods and software for complex pharmacokinetic and pharmacodynamic models with examplesThe AAPS Journal, 2007
- Generalized Moment Theory and Bayesian Robustness Analysis for Hierarchical Mixture ModelsAnnals of the Institute of Statistical Mathematics, 2006
- Bayesian predictive approach to interim monitoring in clinical trialsStatistics in Medicine, 2005
- Sampling-Based Approaches to Calculating Marginal DensitiesJournal of the American Statistical Association, 1990
- Population PharmacokineticsClinical Pharmacokinetics, 1986
- Evaluation of methods for estimating population pharmacokinetic parameters. I. Michaelis-menten model: Routine clinical pharmacokinetic dataJournal of Pharmacokinetics and Biopharmaceutics, 1980